Evaluation of PI3K/AKT/mTOR Signaling Pathway Using BKM120 in Early Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Buparlisib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 01 Apr 2014 According to ClinicalTrials.gov record, the drug BEZ235 is removed from the trial, the trial now has a single treatment arm.
- 01 Apr 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 23 Oct 2012 Planned end date changed from 1 Apr 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.